Capsule Summaries

Share

Program Content

Activities

  • SAVANNAH
    SAVANNAH: Phase II Trial of Savolitinib + Osimertinib for Advanced EGFRm NSCLC With MET Amplification or Overexpression After Progressing on Osimertinib
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 02, 2025

    Expires: October 01, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc